Crossmark

High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD)

Crossref DOI link: https://doi.org/10.1038/s41416-025-03278-w

Published Online: 2025-12-21

Published Print: 2026-03-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nair-Shalliker, Visalini https://orcid.org/0000-0001-6277-5125
Smith, David P. https://orcid.org/0000-0002-1474-3214
Gebski, Val

Patel, Manish I.

Frydenberg, Mark

Yaxley, John

Gardiner, Robert ‘Frank’

Espinoza, David

Kimlin, Michael G.

Dhillon, Varinderpal

Leifert, Wayne

Gillatt, David

Woo, Henry https://orcid.org/0000-0003-4099-0339
Rasiah, Krishan

Awad, Nader

Symons, James

Wells, Jadon K.

Pickett, Hilda A.

Fenech, Michael

Anderson, Paul H.

Armstrong, Bruce K.

Gurney, Howard
Funding

Funding for this research was provided by:

Movember Clinical Trials Award and administered through the Prostate Cancer Foundation Australia (CTA1315).
License Information

Text and Data Mining valid from 2025-12-21

Version of Record valid from 2025-12-21
More Information

Article History

Received: 4 April 2025

Revised: 25 September 2025

Accepted: 14 November 2025

First Online: 21 December 2025

Change Date: 26 February 2026

Change Type: Update

Change Details: In this article the orientation of tab 2 has been changed.

Competing interests

: The authors declare no conflicts of interest.

Document is current

Any future updates will be listed below